Cargando…
Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab
Toripalimab (Junshi Bioscience Co., Ltd) is a new immune checkpoint inhibitor (ICI) that targets programmed cell death protein 1 (PD-1) in various cancers, including metastatic melanoma. No neurological immune-related adverse events (n-irAEs) of toripalimab have been reported, except for neuromuscul...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990884/ https://www.ncbi.nlm.nih.gov/pubmed/35401563 http://dx.doi.org/10.3389/fimmu.2022.850540 |
_version_ | 1784683471877177344 |
---|---|
author | Zhou, Huanyu Xie, Xiaoxi Zhang, Tianyu Yang, Menghan Zhou, Dong Yang, Tianhua |
author_facet | Zhou, Huanyu Xie, Xiaoxi Zhang, Tianyu Yang, Menghan Zhou, Dong Yang, Tianhua |
author_sort | Zhou, Huanyu |
collection | PubMed |
description | Toripalimab (Junshi Bioscience Co., Ltd) is a new immune checkpoint inhibitor (ICI) that targets programmed cell death protein 1 (PD-1) in various cancers, including metastatic melanoma. No neurological immune-related adverse events (n-irAEs) of toripalimab have been reported, except for neuromuscular involvement. We report a case of a 63-year-old woman who presented with severe vertigo, vomiting, nystagmus, cerebellar ataxia, and cognitive impairment after toripalimab treatment for metastatic melanoma. Compared with the concomitant cognitive dysfunction and a pathological reflex involving the cerebral cortex, the signs and symptoms of cerebellar involvement were much more prominent. Anti-glutamic acid decarboxylase 65 (anti-GAD65) antibody was positive in both serum and cerebrospinal fluid (CSF). After intravenous immunoglobulin (IVIG) and methylprednisolone (IVMP) administration, the symptoms of vertigo and vomiting resolved, with cognitive impairment and cerebellar ataxia remaining. This is the first report of autoimmune encephalitis (AIE) as an n-irAE of toripalimab. |
format | Online Article Text |
id | pubmed-8990884 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89908842022-04-09 Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab Zhou, Huanyu Xie, Xiaoxi Zhang, Tianyu Yang, Menghan Zhou, Dong Yang, Tianhua Front Immunol Immunology Toripalimab (Junshi Bioscience Co., Ltd) is a new immune checkpoint inhibitor (ICI) that targets programmed cell death protein 1 (PD-1) in various cancers, including metastatic melanoma. No neurological immune-related adverse events (n-irAEs) of toripalimab have been reported, except for neuromuscular involvement. We report a case of a 63-year-old woman who presented with severe vertigo, vomiting, nystagmus, cerebellar ataxia, and cognitive impairment after toripalimab treatment for metastatic melanoma. Compared with the concomitant cognitive dysfunction and a pathological reflex involving the cerebral cortex, the signs and symptoms of cerebellar involvement were much more prominent. Anti-glutamic acid decarboxylase 65 (anti-GAD65) antibody was positive in both serum and cerebrospinal fluid (CSF). After intravenous immunoglobulin (IVIG) and methylprednisolone (IVMP) administration, the symptoms of vertigo and vomiting resolved, with cognitive impairment and cerebellar ataxia remaining. This is the first report of autoimmune encephalitis (AIE) as an n-irAE of toripalimab. Frontiers Media S.A. 2022-03-25 /pmc/articles/PMC8990884/ /pubmed/35401563 http://dx.doi.org/10.3389/fimmu.2022.850540 Text en Copyright © 2022 Zhou, Xie, Zhang, Yang, Zhou and Yang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Zhou, Huanyu Xie, Xiaoxi Zhang, Tianyu Yang, Menghan Zhou, Dong Yang, Tianhua Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab |
title | Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab |
title_full | Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab |
title_fullStr | Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab |
title_full_unstemmed | Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab |
title_short | Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab |
title_sort | anti-gad65 antibody-associated autoimmune encephalitis with predominant cerebellar involvement following toripalimab treatment: a case report of a novel irae of toripalimab |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990884/ https://www.ncbi.nlm.nih.gov/pubmed/35401563 http://dx.doi.org/10.3389/fimmu.2022.850540 |
work_keys_str_mv | AT zhouhuanyu antigad65antibodyassociatedautoimmuneencephalitiswithpredominantcerebellarinvolvementfollowingtoripalimabtreatmentacasereportofanoveliraeoftoripalimab AT xiexiaoxi antigad65antibodyassociatedautoimmuneencephalitiswithpredominantcerebellarinvolvementfollowingtoripalimabtreatmentacasereportofanoveliraeoftoripalimab AT zhangtianyu antigad65antibodyassociatedautoimmuneencephalitiswithpredominantcerebellarinvolvementfollowingtoripalimabtreatmentacasereportofanoveliraeoftoripalimab AT yangmenghan antigad65antibodyassociatedautoimmuneencephalitiswithpredominantcerebellarinvolvementfollowingtoripalimabtreatmentacasereportofanoveliraeoftoripalimab AT zhoudong antigad65antibodyassociatedautoimmuneencephalitiswithpredominantcerebellarinvolvementfollowingtoripalimabtreatmentacasereportofanoveliraeoftoripalimab AT yangtianhua antigad65antibodyassociatedautoimmuneencephalitiswithpredominantcerebellarinvolvementfollowingtoripalimabtreatmentacasereportofanoveliraeoftoripalimab |